AstraZeneca PLC (AZN)vsDocGo Inc (DCGO)
AZN
AstraZeneca PLC
$158.75
-0.16%
HEALTHCARE · Cap: $263.09B
DCGO
DocGo Inc
$0.67
+15.31%
HEALTHCARE · Cap: $61.74M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20239% more annual revenue ($61.37B vs $301.71M). AZN leads profitability with a 17.0% profit margin vs -62.2%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
DCGO
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.3%
Fair Value
$196.68
Current Price
$158.75
$37.93 discount
Margin of Safety
+65.4%
Fair Value
$2.10
Current Price
$0.67
$1.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while DCGO is a turnaround play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.99 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 36/100), backed by strong 17.0% margins. DCGO offers better value entry with a 65.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a leading mobile healthcare service provider focused on enhancing patient accessibility and optimizing healthcare delivery through its cutting-edge logistics and telehealth solutions. The company specializes in urgent care, diagnostic testing, and health screenings, effectively addressing key healthcare challenges across diverse environments and significantly improving patient experiences. With a strong commitment to innovation and expanding access to healthcare, DocGo is well-positioned in the dynamic healthtech sector, making it an attractive investment opportunity for institutional investors interested in sustainable growth and impactful social contributions.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?